
PRME
Prime Medicine Inc.
$3.24
-$0.20(-5.81%)
61
Overall
--
Value
83
Tech
39
Quality
Market Cap
$488.50M
Volume
3.04M
52W Range
$1.11 - $5.17
Target Price
$6.50
Order:
Income Statement
Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|
REVENUE | |||||
Total Revenue | $294.0K | $168.0K | $3.0M | ||
Total Revenue | $294.0K | $168.0K | $3.0M | ||
GROSS PROFIT | |||||
Gross Profit | $294.0K | $168.0K | $3.0M | ||
OPERATING EXPENSES | |||||
Operating Expenses | $116.5M | $204.8M | $205.4M | ||
Research & Development | $86.7M | $147.9M | $155.3M | ||
Research Expense | $86.7M | $147.9M | $155.3M | ||
Selling, General & Administrative | $29.8M | $43.4M | $50.2M | ||
General & Administrative Expenses | $29.8M | $43.4M | $50.2M | ||
Depreciation & Amortization | $2.2M | $4.7M | $6.1M | ||
Depreciation & Amortization | $2.2M | -- | -- | ||
Other Operating Expenses | $13.2M | $204.8M | $205.4M | ||
OPERATING INCOME | |||||
Operating income | $-116.5M | $-204.8M | $-202.5M | ||
EBITDA | $-114.3M | $-184.4M | $-180.5M | ||
NON-OPERATING ITEMS | |||||
Intinc | -- | $2.8M | $3.5M | ||
Net Non-Operating Interest Income/Expense | -- | $2.8M | $3.5M | ||
Gain on Sale of Securities | -- | -- | $3.5M | ||
Other Income/Expense | $-6.2M | $-274.0K | $-3.5M | ||
Other Special Charges | $-6.2M | $274.0K | $41.0K | ||
SPECIAL ITEMS | |||||
Special Income Charges | -- | $5.7M | -- | ||
PRE-TAX INCOME | |||||
EBIT | $-116.5M | $-198.4M | $-195.9M | ||
Pre-Tax Income | $-122.8M | $-182.5M | $-195.9M | ||
INCOME TAX | |||||
Tax Provision | $-948.0K | $-279.0K | -- | ||
NET INCOME | |||||
Net Income | $-121.8M | $-198.1M | $-195.9M | ||
Net Income (Continuing Operations) | $-121.8M | $-198.1M | $-195.9M | ||
Net Income (Discontinued Operations) | $-121.8M | $-198.1M | $-195.9M | ||
Net Income (Common Stockholders) | $-142.0M | $-198.1M | $-195.9M | ||
TOTALS | |||||
Total Expenses | $116.5M | $204.8M | $205.4M | ||
SHARE & EPS DATA | |||||
Average Shares Outstanding | $33.9M | $91.0M | $118.6M | ||
Average Shares Outstanding (Diluted) | $33.9M | $91.0M | $118.6M | ||
Shares Outstanding | $97.2M | $119.9M | $131.2M | ||
Basic EPS | $-4.19 | $-2.18 | $-1.65 | ||
Basic EPS (Continuing Operations) | $-4.19 | $-2.18 | $-1.65 | ||
Diluted EPS | $-4.19 | $-2.18 | $-1.65 | ||
Diluted EPS (Continuing Operations) | $-4.19 | $-2.18 | $-1.65 | ||
OTHER METRICS | |||||
Accrued Preferred Stock Dividends | $162.2M | $198.1M | -- | ||
Acquired In Process Rn D | -- | $5.7M | -- | ||
Other Gand A | $29.8M | $43.4M | $50.2M | ||
Otherunder Preferred Stock Dividend | $162.2M | $198.1M | -- | ||
Preferred Stock Dividends | $162.2M | $198.1M | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | PRME | $3.24 | -5.8% | 3.04M |
3 | ||||
4 | ||||
5 | ||||
6 |